Please select a video from the list below.
RESPITE Study Results
Recent advances in pulmonary hypertension have led to evolution of strategic approaches to treatment. In patients on therapy, who are exhibiting a decline in function, escalation of combination therapy has been a standard method. The recent RESPITE trial, however, explored the switch of patients, failing on PDE5 inhibitor therapy, to the soluble guanylate cyclase inhibitor, riociguat. Dr. James White describes the rationale, design and principal efficacy and safety results of this important study.
Recent Video
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 1314
ICU Management of PH
ICU Management of PH Views - 186